Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

Additives for energy storage devices comprising cyclodextrin-based compounds and their derivatives are disclosed. The energy storage device comprises a first electrode and a second electrode, where at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, and an electrolyte composition. Cyclodextrin-based compounds may serve as additives to the first electrode, the second electrode, and/or the electrolyte.

Additives for energy storage devices comprising cyclodextrin-based compounds and their derivatives are disclosed. The energy storage device comprises a first electrode and a second electrode, where at least one of the first electrode and the second electrode is a Si-based electrode, a separator between the first electrode and the second electrode, and an electrolyte composition. Cyclodextrin-based compounds may serve as additives to the first electrode, the second electrode, and/or the electrolyte.

The present disclosure provides certain compositions and methods that may be useful in the treatment and/or prevention of a malignant, neurodegenerative, cardiovascular, metabolic, inflammatory, autoimmune, or viral disease or disorder, such as carcinomas, Alzheimer's and Parkinson's disease, multiple sclerosis, Paget's disease, or other aspects of aging, such as atherosclerosis or type-2 diabetes. In some such embodiments, compositions are provided that contain at least one cyclodextrin active agent, such as alpha-cyclodextrin, or an analogue or derivative thereof. In some embodiment the composition is a clathrate of HP-aCD and sodium caprate or caprylate.

The invention provides cyclodextrin inclusion complex delivery vehicles formulated for oral delivery, in which the cyclodextrin inclusion complex comprising N-acetylcysteine and acetaminophen as stacked guest molecules within the cyclodextrin cavity is provided together with an enzyme having a cyclodextrin-degrading activity capable of digesting the cyclodextrin, so that upon delivery of the vehicle to a target the enzyme is activated and releases N-acetylcysteine and acetaminophen from the cyclodextrin cavity. In alternative aspects, these cyclodextrin inclusion complex delivery vehicles are for example provided in the form of medicaments, food ingredients, medical food ingredients, nutritional supplement ingredients, dietary supplement ingredients, herbicides, insecticides, fungicides, animal repellents, pheromones, plant growth regulators, fragrances, fabrics or packaging materials.

Cyclodextrin compositions including one or more radiation polymerizable monomers and a cyclodextrin inclusion complex, the cyclodextrin inclusion complex including a cyclodextrin compound and an olefinic inhibitor of an ethylene generation in produce, are coated onto packaging materials and cured. Treated containers and treated package inserts having the cured cyclodextrin compositions are useful in packaging of respiring plant materials.

Cyclodextrin compositions including one or more radiation polymerizable monomers and a cyclodextrin inclusion complex, the cyclodextrin inclusion complex including a cyclodextrin compound and an olefinic inhibitor of an ethylene generation in produce, are coated onto packaging materials and cured. Treated containers and treated package inserts having the cured cyclodextrin compositions are useful in packaging of respiring plant materials.

The present invention provides a crosslinked polymer composition exhibiting significantly improved elongation at break over conventional ones, and a polymer composition and a polyrotaxane, each of which can be used as a raw material of the crosslinked polymer composition.

The polyrotaxane contains a linear molecule, a cyclic molecule, and a blocking group, wherein the cyclic molecule has a hydrosilyl group. The polymer composition contains the polyrotaxane and a polymer, wherein the polymer has a double bond on at least either a main chain or a side chain. The crosslinked polymer composition is produced by crosslinking of the polymer composition through chemical reaction between the hydrosilyl group of the cyclic molecule and the double bond of the polymer.

The present invention provides a crosslinked polymer composition exhibiting significantly improved elongation at break over conventional ones, and a polymer composition and a polyrotaxane, each of which can be used as a raw material of the crosslinked polymer composition.

The polyrotaxane contains a linear molecule, a cyclic molecule, and a blocking group, wherein the cyclic molecule has a hydrosilyl group. The polymer composition contains the polyrotaxane and a polymer, wherein the polymer has a double bond on at least either a main chain or a side chain. The crosslinked polymer composition is produced by crosslinking of the polymer composition through chemical reaction between the hydrosilyl group of the cyclic molecule and the double bond of the polymer.

Four major polymeric architectures, namely: (a) linear, (b) branched, (c) hyperbranched/dendritic and (d) cross-linked polymers, when formed by reaction of multifunctional alcohols, such as sugar-based alpha-, beta- or gamma-cyclodextrins, with multi-carboxylic acids form unique polyester copolymers. These copolymers have been demonstrated to substantially enhance the water-solubility and bioavailability of water insoluble compounds for a wide variety of uses.